Display Settings:

Format

Send to:

Choose Destination

    Anim Reprod Sci. 2009 May;112(1-2):95-106. Epub 2008 Apr 11.

    Effect of progesterone and/or estradiol treatments prior to induction of ovulation on subsequent luteal lifespan in anestrous Nelore cows.

    Sá Filho OG, Thatcher WW, Vasconcelos JL.

    Departamento de Produção Animal, Faculdade de Medicina Veterinária e Zootecnia-UNESP, Botucatu-SP, Brazil.

    Three experiments evaluated effects of estradiol (E(2)) and/or progesterone (P(4)) prior to induction of ovulation with GnRH on subsequent luteal lifespan in anestrous Nelore cows. In Experiment 1, cows (25-65 days post-partum [DPP]; n=114) were assigned randomly to receive a 6-day treatment with an intravaginal P(4) device (CIDR) and/or 1mg i.m. injection of 17beta-E(2) (4 groups; 2x2 factorial design) prior to ovulation. Blood samples were collected on days 0, 5, 7, 9, 12, 15 and 19 for evaluation of luteal function. Pre-treatment with P(4) reduced occurrence of premature luteolysis (PL; 79.2% in non-treated vs. 13.5% in treated cows; P<0.01), but there was no effect of treatment with 17beta-E(2) on percentage of PL. In Experiment 2, cows (30-40 DPP; n=35) were assigned randomly to receive either 0.5mL i.m. injection of cottonseed oil (placebo) or 1mg i.m. injection of E(2) cypionate. Blood samples were collected on days 0, 5, 9 and 15 for evaluation of luteal function. Incidence of PL (83.0% in Control Group vs. 75.0% in ECP Group; P>0.1) and mean serum P(4) did not differ between treatment groups. In Experiment 3, cows (30-60 DPP; n=109) were randomly assigned to receive either a 6-day (6-d Group) or a 3-day (3-d Group) treatment with CIDR. Blood samples were collected on days 0, 5, 7 and 9 for luteal function evaluation. Incidence of PL (5.5% in 6-day vs. 5.5% in 3-day groups; P>0.1) and mean serum P(4) did not differ between treatment groups. In conclusion, both 3- and 6-day treatments with P(4) prior to induction of ovulation in anestrous Nelore cows increased percentage of normal luteal lifespan, while administration of 1mg of 17beta-E(2) or E(2) cypionate failed to prevent occurrence of PL.

    PMID: 18468816 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Estrogen (Cenestin®, Enjuvia®, Estrace®, ...)

      Estrogen is used to treat hot flushes ('hot flashes'; sudden strong feelings of heat and sweating) in women who are experiencing menopause ('change of life', the end of monthly menstrual periods). Some brands of estrogen...

    • Progesterone (Prometrium®)

      Progesterone is used as a part of hormone replacement therapy in women who have passed menopause (the change of life) and have not had a hysterectomy (surgery to remove the uterus). Hormone replacement therapy usually in...

    • Estrogen Injection (Delestrogen®, DEPO-Estradiol®, Premarin Intravenous®)

      The estradiol cypionate and estradiol valerate forms of estrogen injection are used to treat hot flushes (hot flashes; sudden strong feelings of heat and sweating) and/or vaginal dryness, itching, and burning in women wh...